Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.1

The summary of product characteristics (SmPC) of MAYZENT can be found in the Downloadable resources section or can be viewed on the emc website by clicking here.

 

MAYZENT is now the first and only oral treatment recommended by NICE and SMC for adults living with SPMS with active disease

 

 

 

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
  2. https://www.nice.org.uk/guidance/ta656/resources/siponimod-for-treating-secondary-progressive-multiple-sclerosis-pdf-82609202014405 [Accessed November 2020].
  3. https://www.scottishmedicines.org.uk/media/5468/siponimod-mayzent-final-september-2020-for-website.pdf [Accessed November 2020].
SIP20-C001(1) November 2020
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]